Market Newsdesk

SUNNYVALE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that SSE Enterprise Telecoms, one of the UK’s leading connectivity providers, has selected Infinera’s XTM Series for the second phase of its UK-wide network expansion. The expanded network will bring high-capacity services to more businesses across the UK, further facilitating 5G rollouts, and aiding in the deployment of next-generation connectivity technologies such as the Industrial Internet of Things (IIoT).

With Infinera’s XTM Series, SSE Enterprise Telecoms leverages an industry-leading optical solution optimized for 5G transport with high-performance synchronization capabilities and low latency. The network’s Layer 2 packet optical aggregation features also provide enterprise customers with high-bandwidth connectivity services over the same network. These benefits extend across SSE Enterprise Telecoms’ network, which upon completion will span over 30,000 km, delivering the high-speed, performance, and reach required to support the growing digital needs of UK organizations.

“This network expansion with Infinera’s XTM Series is key to our UK initiative as it enables new technologies including the IIoT and autonomous vehicles, as well as opening the door to new business technologies such as seamless, instant video streaming and immersive virtual and augmented reality,” said Dave Eddy, COO, SSE Enterprise Telecoms. “Infinera’s XTM solution provided the high performance, scalability, and flexibility required to meet our network needs.”

“The UK market’s bandwidth is growing exponentially, and SSE Enterprise Telecoms is poised to meet this growing demand as it more than doubles its number of connected exchanges,” said Nick Walden, Senior Vice President, Sales at Infinera. “We are proud to be a part of SSE Enterprise Telecoms’ network expansion as it ushers the era of 5G with the unique capabilities of Infinera’s XTM.”

Infinera Contacts:

Media:

Anna Vue
Tel. +1 (916) 595-8157
[email protected]

Investors:

Amitabh Passi
Head of Investor Relations
[email protected]

About SSE Enterprise Telecoms

SSE Enterprise Telecoms provides class-leading connectivity and data centre services that deliver very high performance, cost efficiency and a competitive edge. The company operates a 20,000+km private telecoms network and an estate of 90 commercial data centres that span the UK. With its extensive telecoms and data centre operational expertise it offers commercial security with unrivalled in-house engineering resource.

About Infinera

Infinera is a global supplier of innovative networking solutions that enable carriers, cloud operators, governments, and enterprises to scale network bandwidth, accelerate service innovation, and automate network operations. The Infinera end-to-end packet optical portfolio delivers industry-leading economics and performance in long-haul, submarine, data center interconnect, and metro transport applications. To learn more about Infinera, visit www.infinera.com, follow us on Twitter @Infinera, and read our latest blog posts at www.infinera.com/blog.

Infinera and the Infinera logo are registered trademarks of Infinera Corporation.

This press release contains forward-looking statements. These statements are not guarantees of results and should not be considered as an indication of future activity or future performance. Actual results may vary materially from these expectations as a result of various risks and uncertainties. Information about these risks and uncertainties, and other risks and uncertainties that affect Infinera’s business, is contained in the risk factors section and other sections of Infinera’s Quarterly Report on Form 10-Q for the Fiscal Quarter ended September 26, 2020 as filed with the SEC on November 5, 2020, as well as any subsequent reports filed with or furnished to the SEC. These reports are available on Infinera’s website at www.infinera.com and the SEC’s website at www.sec.gov. Infinera assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

PALM BEACH GARDENS, Fla., Dec. 01, 2020 (GLOBE NEWSWIRE) — Integrity Implants Inc., a privately held medical device company dedicated to delivering innovative solutions for spine surgery, today announced the publication of another in a series of recent clinical articles in the International Journal of Spine Surgery (www.ijssurgery.com) highlighting its FlareHawk^® expandable interbody cage. In their paper, Clinical and Radiographic Outcomes After Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS TLIF) – Early Experience Using a Biplanar Expandable Cage for Lumbar Spondylolisthesis (International Journal of Spine Surgery October 2020, 7125; DOI: https://doi.org/10.14444/7125), Lee A. Tan, Joshua Rivera, Xiao A. Tan, Vivian P. Le, Larry T. Khoo, and Sigurd H. Berven demonstrate favorable vertebral body slip or spondylolisthesis reduction accompanied by an increase in segmental lordosis and positive patient-reported outcomes.

The retrospective review of 13 patients treated during a one-year period found a mean slippage reduction of 6.0mm along with an improvement in segmental lordosis, increases in foraminal and posterior disc height, as well as improvement in all radiographic parameters postoperatively. Patient-reported outcome measures including VAS back, VAS leg, and EQ5D also improved across the board. There were no findings of endplate violation, cage subsidence, or cage migration, and there were no reoperations or implant-related complications.

Lee Tan, M.D., Assistant Professor of Neurological Surgery at UCSF Medical Center in San Francisco, California, shares, “My early experience shows good short-term radiographic and clinical outcomes, with almost complete reduction of spondylolisthesis postoperatively in all cases. The absence of nerve root injury is suggestive that the biplanar expandable cage is safe and obviates the need for excessive nerve root retraction during cage insertion.”

As discussed in the article, one possible explanation for the clinical success is that the expansion of the cage in the horizontal plane increases surface area contact with the endplates to better distribute the load and reduce stress, while the multi-material cage design consisting of a titanium shim inserted into a PEEK shell allows the cage to contour to the patient’s endplates, further reducing the risk of endplate violation.

Sigurd Berven, M.D., Professor in Residence, Department of Orthopaedic Surgery at the University of California at San Francisco, adds, “A challenging aspect of the MIS TLIF procedure is inserting the cage through a relatively small surgical corridor with protection of the neural elements. Additionally, in a lordotic disc space, the posterior disc height is typically shorter than the anterior disc height, thus limiting the size of cage that can be inserted posteriorly, potentially limiting the amount of lordosis restoration. In these cases that often present with a collapsed disc space and bone-on-bone pathology, the low-profile, biplanar, and lordotically expanding FlareHawk cage is ideal for reducing risk to the neural elements on insertion of the implant, and for improving the surface area of the implant with the endplate and the restoration of segmental lordosis. After insertion, the cage and prepared disc space can be filled with allograft or autograft to optimize fusion. The results of the study are encouraging regarding the efficacy of MIS fusion using the technique.”

Dr. Tan concludes, “Remarkably, we had no cases of endplate violation or cage subsidence in this cohort. This is significantly lower than the rates reported in the current literature, which range from 6% up to 33%. I believe that the biplanar expansion is key to decreasing the likelihood of subsidence.”

The FlareHawk spinal implant is the flagship product for Integrity Implants and represents the first of its kind in the expandable cage market. Much like coronary stents that offer patients a less-invasive alternative to open-heart procedures, the FlareHawk expandable cage features a PEEK shell that is inserted in a compressed form that can be effectively passed through small neural pathways, and, once within the intervertebral disc space, expanded to a larger footprint and height. An open-architecture titanium shim inserted within the PEEK shell produces the expansion and creates a solid-state construct that is resistant to collapse yet has shown the ability to conform to endplate anatomy to increase surface contact area and lower stresses. The Adaptive Geometry™ and advanced multi-material composition embodied in the FlareHawk device respect patient anatomy both during insertion and for long-term stability. To date, over 8,500 FlareHawk cages have been implanted in more than 6,000 patients.

Chris Walsh, Integrity Implants CEO, adds, “Last month, we shared the encouraging results of a multi-center study highlighting the favorable fusion efficacy and endplate conforming geometry of the FlareHawk cage. This work by surgeons Lee Tan, Sig Berven, and Larry Khoo represents the third peer-reviewed study of the FlareHawk cage this year. Beyond intrinsic cage design and performance, the study addresses a specific pathology solution that resonates with surgeons. It is encouraging to see published literature echo surgeon confidence in the FlareHawk cage, and documenting the application of Adaptive Geometry to the important and increasingly popular MIS TLIF approach is yet another step in confirming our technology as a compelling clinical choice for surgeons.”

About FlareHawk Expandable Lumbar Interbody Fusion System

The FlareHawk Interbody Fusion System is indicated for spinal intervertebral body fusion with autogenous bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone in skeletally mature individuals with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1, following discectomy. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should have at least six (6) months of non-operative treatment. Additionally, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). FlareHawk system spacers are intended to be used with supplemental fixation instrumentation, which has been cleared for use in the lumbar spine.

About Integrity Implants Inc.

Integrity Implants, founded in 2016 by seasoned business partners and spine leaders Chris Walsh and Wyatt Geist, is a privately held medical device company headquartered in Palm Beach Gardens, Florida. The Company is dedicated to delivering innovative spine products and solutions to surgeons and their patients around the globe. Its proprietary Adaptive Geometry™ technology fundamentally respects a patient’s neural, vascular, bony, and soft tissue anatomy, both during and after implantation.

For more information, please visit the Company’s website at www.integrityimplants.com.

Media Contact:

Mark Richards
512-913-9572
[email protected]

THE WOODLANDS, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN), a specialty retailer of furniture and mattresses, home appliances, consumer electronics, home office products and provider of consumer credit, today announced it will host a conference call on December 8, 2020 to discuss its third quarter fiscal year 2021 financial results. The conference call will begin at 10:00 A.M. CT (11:00 A.M. ET). A press release regarding the operating results will be released the same day before the market opens.

Participants can join the call by dialing 877-451-6152 or 201-389-0879. The conference call will also be broadcast simultaneously via webcast on a listen-only basis. A link to the earnings release and webcast will be available at ir.conns.com.

About Conn’s, Inc.

Conn’s HomePlus is a specialty retailer currently operating 140+ retail locations in Alabama, Arizona, Colorado, Florida, Georgia, Louisiana, Mississippi, Nevada, New Mexico, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, and Virginia.

The Company’s primary product categories include:

• Furniture and mattress, including furniture and related accessories for the living room, dining room and bedroom, as well as traditional and specialty mattresses;
• Home appliance, including refrigerators, freezers, washers, dryers, dishwashers and ranges;
• Consumer electronics, including LED, OLED, QLED, Ultra HD, and internet-ready televisions, gaming consoles, home theater and portable audio equipment; and
• Home office, including computers, printers and accessories.

Additionally, Conn’s HomePlus offers a variety of products on a seasonal basis. Unlike many of its competitors, Conn’s HomePlus provides flexible in-house credit options for its customers in addition to third-party financing programs and third-party lease-to-own payment plans.

CONN-G
Investor Contact:
S.M. Berger & Company
Andrew Berger, (216) 464-6400

CARLISLE, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) — Joining the global movement designed to celebrate philanthropy and encourage social good, this Giving Tuesday, The GIANT Company will recognize and thank six community partners in Pennsylvania that share its purpose of connecting families for a better future. GIANT Company will award product and financial donations totaling $25,000 to six local nonprofit organizations across Pennsylvania.

“Of the many lessons we’ve learned this year, one is the lasting impact an act of kindness can have and how we can change the world by giving back,” said Emily Steinkamp, social impact manager at The GIANT Company. “While The GIANT Company works 365 days a year to help make our neighborhoods and families stronger, surprising some of our incredible nonprofit partners on Giving Tuesday is a way for us to say thanks for the care and support they’ve provided to their community in a year unlike any other.”

This year, The GIANT Company is thanking the following nonprofit organizations with donations:

• Autism Wings – Located in Plymouth Meeting, Pa., the nonprofit works to lift up the needs of individuals with autism, as well as their families and caregivers. Autism Wings has been raising funds for the Autismobile, an RV that will be converted to a mobile service delivery unit to meet clients at their homes. This donation will provide funds for the purchase and upgrades of this vehicle.

• Big Heart Harvest – Based in Douglasville, Pa., the organization feeds the hungry by distributing goods to local soup kitchens and rescue missions, as well as personal delivery to families in need. Big Heart Harvest will use the donation to care for and provide food for chickens, whose eggs are given freely to rescue missions, soup kitchens and individuals in need.

• Capital Area Head Start – Serving families across Harrisburg, Pa., the nonprofit prepares children and families for success in school and life while supporting children’s health and well-being. A program of Keystone Human Services, The GIANT Company’s donation will allow the organization to continue to provide nutritious and hot meals for families in need.

• Carlisle Area Family Life Center – Headquartered in The GIANT Company’s hometown, the Carlisle Area Family Life Center aims to provide support, education, and practical assistance in a loving way to women and families. The GIANT Company will provide pallets of diapers, formula, wipes and baby supplies to families in need.

• Power Packs Project – Located in Lancaster, Pa., the nonprofit empowers families with education and ingredients to create nutritious weekend meals, so their children return to school fed and ready to learn. Funds from The GIANT Company will help provide holiday dinners to the over 1,000 families served.

• Shiremanstown Fire Department – The volunteer fire department serves the borough of Shiremanstown, Pa., and provides mutual aid response to neighboring townships. The fire department will use this donation to purchase training aids for members.

“Thanks to this generous gift from The GIANT Company, Autism Wings is now one step closer to soaring into our community,” said Angela Walden, founder and CEO, Autism Wings. “This donation will go toward the purchase of what is probably the most crucial element of our services, a recreational vehicle. We will convert this vehicle into a mobile work, play, social, and break space, bringing our services to the front door of youth with autism who live in our community.”

The GIANT Company’s Giving Tuesday donation continues the company’s longstanding tradition of giving back during the holiday season. Last month, the company donated a record-breaking 10,000 turkeys to 28 partner food banks located across its footprint in time for Thanksgiving. Team members from GIANT and MARTIN’S also contributed 500 volunteer hours to help pack boxes and restock shelves in advance of the busy holiday season. The GIANT Company is also hosting an in-store food drive through Thursday, Dec. 3 to further stock the shelves of community hunger relief organizations.

Established in 2012, Giving Tuesday falls on the Tuesday after Thanksgiving and kicks off the charitable season, when many focus on holiday and end-of-year giving. Charities, families, businesses, and community centers alike come together for one common purpose: to celebrate generosity and to give back. For more information, visit www.givingtuesday.org.

About
The
GIANT Company

The GIANT Company
 
believes that no matter where or how, when meals happen, families connect, and when families connect meaningfully, good happens. Guided by its brand platform, For Today’s Table™, the omni-channel retailer proudly serves millions of neighbors across Pennsylvania, Maryland, Virginia and West Virginia. A Great Place to Work™ certified company with more than 35,000 talented team members supporting nearly 190 stores, 132 pharmacies, 105 fuel stations, and over 145 online pickup hubs and grocery delivery service in hundreds of zip
codes, The GIANT Company is changing the customer experience and connecting families for a better future. Founded in 1923 in Carlisle, Pa., The GIANT Company family of brands includes GIANT, MARTIN’S, GIANT Heirloom Market, GIANT Direct and MARTIN’S Direct. The GIANT Company is a company of Ahold Delhaize USA. For more information, visit the
 

GIANT

 
or
 

MARTIN’S

 
websites.

CONTACT:
Ashley Flower
860-966-1727
[email protected]

CALGARY, Alberta, Dec. 01, 2020 (GLOBE NEWSWIRE) — Shaw Communications Inc. (“Shaw”) announced today that it has given the registered shareholders of its Cumulative Redeemable Floating Rate Class 2 Preferred Shares, Series B (the “Series B Shares”) notice of dividend rates.

The Floating Quarterly Dividend Rate for the Series B Shares was set at 2.109% for the Quarterly Floating Rate Period from and including December 31, 2020 to, but excluding, March 31, 2021. The Floating Quarterly Dividend Rate will be reset every quarter.

The Series B Shares are listed on the Toronto Stock Exchange under the ticker symbol SJR.PR.B.

About Shaw Communications Inc.

Shaw Communications Inc. is a leading Canadian connectivity company. The Wireline division consists of Consumer and Business services. Consumer serves residential customers with broadband Internet, Shaw Go WiFi, video and digital phone. Business provides business customers with Internet, data, WiFi, digital phone, and video services. The Wireless division provides wireless voice and LTE data services through an expanding and improving mobile wireless network infrastructure.

Shaw is traded on the Toronto and New York stock exchanges and is included in the S&P/TSX 60 Index (Symbol: TSX – SJR.B, SJR.PR.A, SJR.PR.B, NYSE – SJR, and TSXV – SJR.A). For more information, please visit www.shaw.ca.

For further information, please contact:
Shaw Investor Relations [email protected]

VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) — AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

“Kathy’s extensive healthcare experience and industry insight are a welcome addition to AVITA’s leadership team,” said Dr. Mike Perry, AVITA Therapeutics’ Chief Executive Officer. “In particular her broad operational experience within Regenerative Medicine will be critically important as we seek to bring our pipeline products through development and into the markets.”

Ms. McGee joins AVITA with over 25 years of biopharmaceutical and life sciences experience, most recently serving as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry. Prior to CnA Consulting, Ms. McGee was the Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President of Operations and General Manager, with responsibility for the company’s manufacturing operations in La Jolla, CA. She has also held senior Operations leadership roles at Smith and Nephew and Advanced Tissue Sciences. She earned her Bachelor of Science in chemistry and mathematics from University College Galway Ireland, and holds a Master’s degree in Business and Management from Webster University.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA
THERAPEUTICS, INC.

AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics’ patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES^® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics’ first U.S. product, the RECELL^® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE – RECELL^® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.
To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates.
Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain.
Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control.
Investors should not place considerable reliance on the forward-looking statements contained in this letter.
Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties.
The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

BASKING RIDGE, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — Verizon Fios and AT&T SportsNet Pittsburgh have reached a long-term agreement to relaunch the regional sports network to Fios customers in the Pittsburgh and Harrisburg areas. Relaunching AT&T SportsNet, the broadcast home of the Pittsburgh Pirates and Pittsburgh Penguins, allows baseball and hockey fans in the region to enjoy watching their local teams in the upcoming seasons. 

Fios TV customers can watch a wide range of programming on AT&T SportsNet Pittsburgh beginning Tuesday, December 1st. AT&T SportsNet will be viewable in the Pittsburgh area on channels 76 and 1525, and in HD on channel 576. In the Harrisburg area, AT&T SportsNet Pittsburgh will be available on channels 78 and 1527, and in HD on channel 578. AT&T SportsNet alternate is available in both Pittsburgh and Harrisburg on channels 81 and 1528, and in HD on channel 581 when there are programming conflicts on AT&T SportsNet’s primary channels.

Verizon today issued the following statement:

“Verizon is pleased to reach an agreement with AT&T SportsNet Pittsburgh that enables us to offer the channel to Fios TV customers. We look forward to carrying AT&T SportsNet Pittsburgh so Fios customers can focus on cheering for the Pirates and Penguins in the weeks and years to come.”

AT&T SportsNet Pittsburgh issued the following statement:

“We are very pleased that Verizon Fios customers who are fans of the Pittsburgh Pirates and Penguins will again have access to watch their favorite teams’ games.”

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is celebrating its 20th year as one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $131.9 billion in 2019. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at https://www.verizon.com/about/media-center. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Verizon Fios Media Contact:

Andrew Kameka
[email protected]

AT&T SportsNet Media Contact
:

Randi Lackscheide
[email protected]

NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2020 Annual Meeting of Stockholders to be held on Thursday, December 3, 2020, beginning at 11:00 a.m. EST.

The Annual Meeting of Stockholders and webcast can be accessed via www.virtualshareholdermeeting.com/GALT2020 .

Please log in approximately 10 minutes before the event to ensure a timely connection.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation for NASH cirrhosis by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Contact

Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02